2019
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI, Leighl NB, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N, Tashbar J, Yankelevitz D, Altorki N. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. Journal Of Clinical Oncology 2019, 38: 753-766. PMID: 31829901, DOI: 10.1200/jco.19.02748.Peer-Reviewed Original ResearchConceptsCurative-intent therapyLung cancerStage IFluorodeoxyglucose positron emission tomography/Evidence-based guideline recommendationsNew primary lung cancerRetrospective comparative observational studySurveillance strategiesSmall cell lung cancerBrain magnetic resonance imagingLiterature searchPositron emission tomography/Lung cancer surveillanceCurative-intent treatmentPrimary lung cancerRecurrence-free survivalCell lung cancerDetection of recurrenceComparative observational studyEmission tomography/Optimal imaging modalityEvidence-based recommendationsOutcomes of interestQuality of lifeMagnetic resonance imaging
2018
Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement
Rivera MP, Tanner NT, Silvestri GA, Detterbeck FC, Tammemägi MC, Young RP, Slatore CG, Caverly TJ, Boyd CM, Braithwaite D, Fathi JT, Gould MK, Iaccarino JM, Malkoski SP, Mazzone PJ, Tanoue LT, Schoenborn NL, Zulueta JJ, Wiener RS. Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement. American Journal Of Respiratory And Critical Care Medicine 2018, 198: e3-e13. PMID: 30004250, DOI: 10.1164/rccm.201805-0986st.Peer-Reviewed Original ResearchConceptsLung cancer screeningRisk of deathPatient selectionChronic illnessCancer screeningLung cancerOfficial American Thoracic Society Research StatementHarms of LCSImplementation of LCSScreen-detected lung cancersChronic obstructive pulmonary diseaseRisk of comorbiditiesObstructive pulmonary diseaseEffect of comorbidityLung cancer deathsTreatment-related harmsLung cancer riskBalance of benefitsPulmonary diseaseCancer deathBaseline riskCancer riskComorbiditiesHealthy individualsInternational clinicians
2017
Extending the Reach of Evidence-Based Medicine A Proposed Categorization of Lower-Level Evidence
Detterbeck FC, Gould MK, Lewis SZ, Patel S. Extending the Reach of Evidence-Based Medicine A Proposed Categorization of Lower-Level Evidence. CHEST Journal 2017, 153: 498-506. PMID: 28923759, DOI: 10.1016/j.chest.2017.09.006.Peer-Reviewed Original Research
2010
Coping with the unexpected at surgery
Detterbeck FC, Terrien CM. Coping with the unexpected at surgery. Expert Review Of Respiratory Medicine 2010, 4: 115-122. PMID: 20387297, DOI: 10.1586/ers.09.59.Peer-Reviewed Original ResearchConceptsLung cancer surgeryMultidisciplinary tumor boardN2 node involvementPN2 diseaseNode involvementT4 tumorsExperienced centersSuch patientsCancer surgeryPreoperative assessmentTumor boardChest wallBetter outcomesIntraoperative surprisesSurgeryResectionMediastinalPatientsTumorsCareful planningDisease
2006
Clinical Value of the WHO Classification System of Thymoma
Detterbeck FC. Clinical Value of the WHO Classification System of Thymoma. The Annals Of Thoracic Surgery 2006, 81: 2328-2334. PMID: 16731193, DOI: 10.1016/j.athoracsur.2005.11.067.Peer-Reviewed Original ResearchConceptsWHO systemWorld Health Organization histologic classification systemWHO classification systemIndependent prognostic valueDistinct patient groupsHistologic classification systemClinical management decisionsWHO typePrognostic valuePatient groupClinical valueMultivariate analysisClassification systemThymoma